Does Sativex (THC/CBD spray) have abuse potential? Evidence says low risk
Across clinical trials, Sativex produced low intoxication scores, euphoria in only 2.2% of patients, no tolerance development, and no withdrawal syndrome upon stopping.
Quick Facts
What This Study Found
This review compiled safety data from all published Sativex clinical trials, including the integrated safety analysis for multiple sclerosis patients. Intoxication scores were consistently low. Only 2.2% of patients reported euphoria.
Tolerance did not develop over extended use, meaning patients did not need increasing doses for the same effect. When patients stopped Sativex abruptly, no formal withdrawal syndrome occurred. No cases of abuse or diversion were reported.
A separate formal abuse liability study in recreational cannabis users showed Sativex had some abuse potential at higher doses compared to placebo, but scores were consistently lower than equivalent doses of pure THC (dronabinol).
Key Numbers
Euphoria reported by 2.2% of patients. No tolerance development. No withdrawal syndrome on abrupt cessation. Abuse liability scores consistently lower than equivalent THC doses.
How They Did This
Review of all published clinical trial data for Sativex, plus GW Pharmaceuticals' integrated safety database for MS patients. Also referenced a formal abuse liability study comparing Sativex to dronabinol in recreational cannabis users.
Why This Research Matters
Any THC-containing medicine raises concerns about abuse potential. This evidence suggested that the 1:1 THC:CBD formulation and oromucosal delivery route of Sativex produced substantially less abuse liability than pure THC or smoked cannabis.
The Bigger Picture
The low abuse potential of Sativex supported the idea that CBD may modulate the rewarding effects of THC. This had implications for how cannabinoid medicines are formulated and regulated.
What This Study Doesn't Tell Us
Review compiled by a single author associated with cannabis medicine research. Clinical trial populations (MS patients) may differ from recreational users in their responses. The formal abuse liability study used recreational users, which represents a high-risk population.
Questions This Raises
- ?Does CBD directly reduce THC's euphoric effects, or does the delivery route matter more?
- ?Would abuse potential change with long-term access?
- ?How do these findings apply to other THC:CBD combinations?
Trust & Context
- Key Stat:
- Only 2.2% of Sativex patients reported euphoria
- Evidence Grade:
- Review of clinical trial safety data. Comprehensive dataset but author was associated with the field of cannabis medicine.
- Study Age:
- Published in 2011. Sativex has accumulated more post-marketing safety data since this review.
- Original Title:
- Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
- Published In:
- Expert opinion on drug safety, 10(5), 675-85 (2011)
- Authors:
- Robson, Philip(4)
- Database ID:
- RTHC-00515
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can you get high from Sativex?
In clinical trials, intoxication scores were low and only 2.2% of patients reported euphoria. The combination of THC with CBD and the slow oromucosal absorption route appears to reduce psychoactive effects compared to smoking cannabis.
Why does Sativex have less abuse potential than pure THC?
Two factors likely contribute: CBD may modulate THC's rewarding effects, and oromucosal spray delivers THC more slowly than smoking, reducing the rapid onset "rush" associated with abuse potential.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-epilepsy-CBD-Epidiolex
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- medical-benefits-of-cannabis
- quitting-weed-and-alcohol
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- rehab-for-weed-addiction-necessary
- seniors-older-adults-cannabis-risks-medications
- signs-of-cannabis-use-disorder
- weed-breastfeeding-THC-breast-milk
- weed-vape-pen-addiction
- being-high-247-brain-body-constant-thc
- optimal-tolerance-break-length-reset-timing
- what-happens-body-high-247-for-months
Cite This Study
https://rethinkthc.com/research/RTHC-00515APA
Robson, Philip. (2011). Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.. Expert opinion on drug safety, 10(5), 675-85. https://doi.org/10.1517/14740338.2011.575778
MLA
Robson, Philip. "Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.." Expert opinion on drug safety, 2011. https://doi.org/10.1517/14740338.2011.575778
RethinkTHC
RethinkTHC Research Database. "Abuse potential and psychoactive effects of δ-9-tetrahydroca..." RTHC-00515. Retrieved from https://rethinkthc.com/research/robson-2011-abuse-potential-and-psychoactive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.